New for 2020, The Cell-Based Immunotherapy stream focuses on the latest protein engineering, clinical and analytical strategies driving the development of cell-based immunotherapies such as CAR Ts, TCRs, TILs and NKs, for the treatment of cancer and immune disorders. Topics include improving target identification, optimizing product design, specificity, safety, characterization and analytics.

Conferences Include:

August 31 - September 1

Improving Immunotherapy Efficacy and Safety

September 2-3

CAR Ts, TCRs and TILs

September 3-4

Cell and Gene Therapy Analytics

Keynote Speakers:

Prasad Adusumilli, MD, FACS, FCCP, Deputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma

Adrian Bot, PhD, Vice President, Translational Medicine, Kite Pharma, a Gilead Company

Jan Joseph (Jos) Melenhorst, PhD Adjunct Associate Professor, Pathology & Laboratory Medicine, University of Pennsylvania

Jeffrey Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota

2024 PROGRAMS

View By:

• Display of Biologics
• Engineering Antibodies
• Machine Learning for Protein Engineering

• Antibodies for Cancer Therapy
• Emerging Targets for Oncology
• Antibody Drug Conjugates

• TS: Intro to Bispecifics
• Advancing Bispecific Antibodies
• Engineering Bispecific Antibodies

• Advances in Immunotherapy
• Cell-Based Immunotherapy
• In vivo Cell and Gene Engineering

• Difficult-to-Express Proteins
• Optimizing Protein Expression
• Protein Production Workflows

• Digital Integration in Biotherapeutic Analytics
• Biophysical Methods
• Characterization for Novel Biotherapeutics

• TS: Intro to Immunogenicity
• Immunogenicity Assessment and Management
• TS: Intro to Bioassays

• Emerging Indications for Therapeutic Antibodies
• mRNA Therapeutics
• In vivo Cell and Gene Engineering